Roche Reveals Update from Phase III persevERA Study Targeting ER-Positive Advanced Breast Cancer; Ipsen Confirms Voluntary Withdrawal of TAZVERIK for Select Oncology Indications; Bristol Myers Squibb Unveils Positive Phase 3 Data from SUCCESSOR-2 Study Evaluating Mezigdomide in R/R Multiple Myeloma; Servier Announces Acquisition of Day One Biopharmaceuticals to Bolster Rare Cancer Portfolio; Pfizer Advances Trispecific Antibody with Positive Phase 2 Results in Atopic Dermatitis

Roche Announces Latest Findings from Phase III persevERA Study in ER-Positive Advanced Breast Cancer

Roche announced results from the Phase III persevERA Breast Cancer study evaluating the investigational oral selective estrogen receptor degrader (SERD) giredestrant in combination with the CDK4/6 inhibitor palbociclib for patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer.

The study assessed whether the combination therapy could improve outcomes compared with standard endocrine therapy combined with a CDK4/6 inhibitor in patients whose disease had progressed following prior treatment. Results demonstrated that the giredestrant-based regimen significantly improved progression-free survival (PFS), meaning it delayed the worsening or progression of the disease compared with the standard-of-care comparator arm.

Giredestrant is designed to degrade the estrogen receptor, which plays a critical role in the growth of many breast cancers. Unlike some existing treatments, it is administered orally and aims to overcome resistance mechanisms that often develop with endocrine therapy. According to Roche, these findings reinforce the potential of giredestrant as an important next-generation endocrine therapy for hormone-receptor–positive breast cancer.

The persevERA trial is part of Roche’s broader clinical development program evaluating giredestrant across different treatment settings, including early-stage disease and first-line advanced disease. Previous studies, such as evERA and lidERA have also shown promising results supporting its potential role across the breast-cancer treatment continuum.

Investigators noted that resistance to endocrine therapies remains a major challenge in ER-positive breast cancer, particularly after exposure to CDK4/6 inhibitors. The giredestrant combination approach may provide an additional treatment option aimed at delaying disease progression and improving patient outcomes.

Roche plans to present the detailed data at upcoming scientific meetings and discuss the results with health authorities. If supported by further evidence and regulatory review, giredestrant could potentially become a new treatment standard for patients with advanced hormone-receptor–positive breast cancer who have limited options after disease progression. 

Ipsen Withdraws TAZVERIK (tazemetostat) for Follicular Lymphoma and Epithelioid Sarcoma

Ipsen announced that it will voluntarily withdraw the cancer medicine TAZVERIK (tazemetostat) from the market for the treatment of follicular lymphoma and epithelioid sarcoma. The decision follows emerging safety data from the ongoing Phase Ib/III SYMPHONY-1 clinical trial.

TAZVERIK is an inhibitor of the EZH2 methyltransferase enzyme and has previously been approved for certain patients with follicular lymphoma and epithelioid sarcoma. However, the Independent Data Monitoring Committee (IDMC) overseeing the SYMPHONY-1 study identified cases of secondary hematologic malignancies in patients receiving treatment regimens that included tazemetostat. Based on this emerging safety signal, the committee concluded that the potential risks may outweigh the expected clinical benefits for patients in this setting.

Following the recommendation of the IDMC, Ipsen decided to withdraw TAZVERIK in all indications across its markets, effective immediately. The company stated that patient safety remains its highest priority and that the withdrawal reflects a precautionary measure in response to the safety findings.

Ipsen is working with health authorities and healthcare professionals to ensure an orderly discontinuation of the therapy and to provide guidance for physicians treating patients currently receiving TAZVERIK. Physicians are advised to discuss alternative treatment options with affected patients and manage therapy transitions appropriately.

The SYMPHONY-1 trial had been evaluating tazemetostat in combination with lenalidomide and rituximab compared with the lenalidomide-rituximab regimen alone in patients with follicular lymphoma. The trial’s safety findings prompted the reassessment of the drug’s overall benefit-risk profile.

Ipsen noted that it remains committed to advancing its oncology pipeline and continues to invest in innovative treatments for cancers with high unmet medical need. The withdrawal of TAZVERIK underscores the importance of ongoing clinical monitoring to ensure that approved medicines maintain a favorable safety profile for patients. 

Bristol Myers Squibb Shares Encouraging Phase 3 SUCCESSOR-2 Results for Mezigdomide in R/R Multiple Myeloma

Bristol Myers Squibb announced positive interim Phase III results from the SUCCESSOR-2 clinical trial, evaluating mezigdomide combined with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM).

The study demonstrated that the regimen containing mezigdomide achieved a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with the control regimen of carfilzomib plus dexamethasone alone. Progression-free survival measures the time during and after treatment in which the disease does not worsen.

Mezigdomide is part of the company’s CELMoD platform, a next-generation class of immunomodulatory drugs designed to enhance immune-mediated destruction of cancer cells while improving potency compared with earlier IMiD therapies. The compound works through targeted protein degradation mechanisms that promote the elimination of proteins involved in tumor growth.

Patients enrolled in SUCCESSOR-2 had multiple myeloma that had relapsed or no longer responded to previous therapies, including anti-CD38 antibodies and lenalidomide. These patients often have limited treatment options, highlighting the importance of new therapeutic strategies.

Safety findings from the trial were consistent with the known safety profile of mezigdomide and the drug combination. Patients in the study will continue to be followed for overall survival, long-term safety, and other clinical endpoints.

Bristol Myers Squibb plans to present the full data from the trial at an upcoming medical conference and intends to discuss the results with regulatory authorities. The positive findings strengthen confidence in the company’s CELMoD platform and support the continued development of mezigdomide as a potential new treatment option for patients with difficult-to-treat multiple myeloma. 

Servier to Acquire Day One Biopharmaceuticals to Strengthen Rare Oncology Portfolio

Servier announced that it has entered into a definitive agreement to acquire Day One Biopharmaceuticals for approximately $2.5 billion. The acquisition is intended to strengthen Servier’s presence in rare oncology, particularly in pediatric cancers.

Under the terms of the agreement, Servier will acquire all outstanding shares of Day One for $21.50 per share in cash, representing a significant premium compared with the company’s recent trading price. The transaction will be executed through a tender offer followed by a merger once the required number of shares has been acquired.

Day One Biopharmaceuticals focuses on developing targeted therapies for life-threatening diseases affecting both children and adults. Its pipeline includes treatments designed for pediatric low-grade glioma, a rare childhood brain tumor with limited treatment options. By acquiring Day One, Servier aims to enhance its portfolio of innovative oncology therapies and expand its pipeline across multiple stages of development.

The deal aligns with Servier’s long-term strategy and 2030 ambition to advance innovative treatments for cancers with high unmet medical needs. The combined expertise of Servier and Day One is expected to accelerate research and development and broaden global access to novel cancer therapies.

The servier intends to fund the acquisition using existing cash and investments. The transaction is subject to customary closing conditions, including regulatory approvals and acceptance of the tender offer by a majority of Day One shareholders. The companies expect the acquisition to close in the second quarter of 2026.

Following completion, Day One’s scientific capabilities and pipeline will be integrated into Servier’s global oncology operations, reinforcing its commitment to developing targeted therapies for rare cancers.

Pfizer Reports Positive Phase 2 Results for Trispecific Antibody in Moderate-to-Severe Atopic Dermatitis

Pfizer reported positive topline results from a Phase II clinical trial evaluating the investigational trispecific antibody tilrekimig (PF-07275315) in adults with moderate-to-severe atopic dermatitis, a chronic inflammatory skin disease.

The trial met its primary endpoint, demonstrating a statistically significant increase in the proportion of patients achieving EASI-75, defined as at least a 75% reduction in the Eczema Area and Severity Index at Week 16 compared with placebo. Across tested doses, placebo-adjusted response rates ranged from approximately 38.7% to 51.9%, indicating meaningful clinical improvements in disease severity.

Tilrekimig is designed as a trispecific antibody targeting three inflammatory pathways simultaneously, interleukin-4 (IL-4), interleukin-13 (IL-13), and thymic stromal lymphopoietin (TSLP). These pathways play key roles in Type-2 immune responses that drive conditions such as atopic dermatitis, asthma, and chronic obstructive pulmonary disease (COPD). By blocking all three pathways with a single therapy, tilrekimig aims to provide broader and more durable control of inflammation.

The drug demonstrated a favorable safety and tolerability profile during the trial. The study also evaluated different monthly dosing regimens, and results suggested that a once-monthly administration could deliver competitive efficacy relative to existing biologic therapies.

Based on these encouraging findings, Pfizer plans to advance tilrekimig into Phase III development, with a pivotal trial in atopic dermatitis expected to begin later in 2026. If successful, the therapy could become a first-in-class trispecific antibody for treating chronic inflammatory diseases.

The results strengthen Pfizer’s inflammation and immunology pipeline and highlight the growing role of multi-target antibody therapies in addressing complex immune-mediated diseases.